CHO Plus was founded in 2014 with the mission of increasing the productivity of cells used for manufacturing life-saving therapeutic proteins for treating human disease (such as antibodies for the treatment of cancer). For many years little was done to advance this area. CHO Plus has developed patented cell engineering technology to increase the amount of protein-producing “machinery” (i.e.
endoplasmic reticulum and Golgi apparatus) within each cell. Initial studies demonstrate the potential for increasing cell productivity by up to 450%. This could lower pharmaceutical industry production costs by billions of dollars per year, in aggregate, if widely adopted.
Therapeutic proteins such as antibodies, enzymes, and hormones are used to treat diseases such as cancer, heart attacks, arthritis, and many other conditions. The therapeutic protein market is expected to grow to US$ 300 billion by 2025.